Chafing occurs when the skin rubs against something, such as clothing, for a prolonged period. The friction can cause a painful rash that typically resolves when the chafing stops.

A person can experience chafing on any part of the body that encounters friction. The resulting rash is often minor, but there are some possible complications.

In this article, we look at what causes chafing rash and how to treat it. We also look at how a person can prevent chafing from occurring.

A chafing rash occurs anywhere on the body where the skin is rubbing against clothing or other skin.

Mild chafing rashes tend not to be too painful, but more serious rashes could bleed, crust, or blister. Chafing can occur anywhere where there is friction, but some areas of the body are more prone to chafing than others.

Areas where chafing is most likely to happen are generally moist or generate friction. They include the:

The direct cause of chafing is the skin is rubbing against something for a prolonged period. This could happen, for instance, when someone is walking and their inner thighs are rubbing together.

Chafing is more likely to occur in particular areas of the body, and it tends to happen during physical activity, such as running.

Others causes of chafing include:

Additionally, an infant or toddler wearing a diaper may experience chafing due to the added moisture and movement in the area.

Learn more about the types of diaper rash here.

Chafing causes a burning or stinging rash to occur where the skin is rubbing against something. The rash will not spread to other areas.

Possible complications of chafing rashes include:

Bacteria could enter through the broken or damaged skin around a chafing rash and cause an infection. For that reason, a person should make sure that they take care of the rash and keep it clean. The Centers for Disease Control and Prevention (CDC) list several symptoms of a skin infection, which include:

Chafing rashes will typically clear up within a few days if a person stops the activity causing the chafing or takes action to prevent further chafing.

Excessive moisture and skin friction may lead to skin breakdown. Patting the skin dry to remove excess moisture may prevent complications of chafing rash.

A person may also wish to consider applying shea butter lotion to the rash. A 2012 study found that shea butter has anti-inflammatory properties, which could make it a good option for people who want to soothe a chafing rash with cream.

For pain, a person can try applying aloe vera to the skin, as it may soothe sore skin and help prevent infections.

People have also traditionally used a range of other plant oils, including olive oil and coconut oil, to treat skin-related issues. Further research is necessary to confirm the benefits of each of these oils.

Unless the skin becomes infected, doctors do not have a standard way of treating chafing rash. A person should avoid the activity that caused the chafing. If they cannot avoid the activity, they should take steps to prevent further chafing from occurring.

If a person needs treatment, a doctor may prescribe or recommend a corticosteroid cream or ointment to help reduce the inflammation resulting from the rash.

It is not always possible to prevent chafing from occurring, but a person can take certain steps to reduce the risk.

According to the American Academy of Dermatology Association, these steps include:

Other steps a person can take to help prevent chafing include:

Additionally, the findings of an older study suggest that a person can apply petroleum jelly to the skin to minimize friction and prevent chafing rash.

If a person develops a rash that spreads, it is likely not a chafing rash. A person should consider seeing their doctor if the rash does not go away within a few days of home treatment.

A person should also talk to their doctor if they suspect that their rash has become infected. A doctor can examine the rash and determine whether additional treatment is necessary.

A chafing rash is often a mild rash that occurs when skin rubs against clothing or other areas of skin. Many cases are mild and will go away when a person stops the activity causing the chafing.

A possible complication of chafing rash is a skin infection. A person should speak with their doctor if the rash is severe or they think that it has become infected.

At-home treatments for chafing rash include aloe vera and other soothing ointments. A person can take preventive steps to reduce the risk of a rash forming, such as wearing moisture-wicking clothing and applying petroleum jelly to areas prone to chafing.

Read more:
What causes chafing rash? Remedies, treatment, and prevention - Medical News Today

Skin Stem Cells Comments Off on What causes chafing rash? Remedies, treatment, and prevention – Medical News Today | December 24th, 2020

Rashes can appear differently on different skin tones. For example, a heat rash on darker skin may look like a series of gray or white spots, while many medical sources describe them as red.

It is crucial for medical professionals to understand how health issues can present on the full range of skin tones. A lack of this understanding can lead to misdiagnoses.

It is generally advisable to contact a doctor about any rash that lasts longer than a week. The Skin of Color Society offer a database of dermatologists in the United States who have experience treating conditions in people of color.

In this article, we explore what rashes can look like on skin of color. We also describe the symptoms and treatments of specific issues.

The appearance of a rash varies with skin tone. On skin of color, a rash may be purple, gray, or white while medical texts often simply describe these rashes as red. Some redness may appear, but typically not very much.

This is due to melanin, a molecule that gives the skin and hair their color. Generally, the more melanin a person has in their skin, the darker their skin tone. It affects how the skin reacts to sunlight, damage, and health conditions that cause rashes.

Some doctors are unaware of how skin conditions present on darker skin. A 2018 study of four major medical textbooks found that darker skin tones were underrepresented in the imagery.

The studys authors report that while, at the time, 20.4% of the U.S. population was Black, only 4.5% of the photographs in the textbooks showed people with dark skin. They suggest that this is likely an example of racial bias in the healthcare system.

Below, we explore how various health issues can appear in skin of color.

Heat rash, sweat rash, and prickly heat are all common names for miliaria, a skin condition that occurs when the skins sweat ducts become blocked.

The symptoms of heat rash include:

On darker skin, the blisters may be gray or white.

This rash often occurs due to heat and humidity, but intense exercise, nonbreathable clothing, and medical dressings can also cause it. The condition typically improves within 12 days.

Cooling down, wearing more breathable clothing, and changing or, if recommended, removing dressings can help.

Eczema causes patches of dry, itchy skin, and the affected area may also be flaky or scaly. If the skin is very dry, it may crack or bleed.

In darker skin tones, patches of eczema may be red, pink, magenta, or darker than surrounding skin.

Eczema is also more likely to form in specific ways in people of color. For example, there is a higher chance that the rash may be papular, characterized by a series of small bumps like goosebumps.

There are several types of eczema, including:

This occurs when the skin comes into contact with an irritant, such as poison ivy, nickel, or fragrance. The skin may itch, sting, burn, or blister.

People with certain jobs have a higher risk of contact dermatitis. These jobs may involve regular contact with chemicals, food, or water. People with a higher risk may include:

Avoiding contact with the trigger, such as a specific chemical, is the best approach. A dermatologist can also describe products that can help and perform skin allergy testing to identify the trigger.

Atopic dermatitis is eczema with no clear cause. The condition often begins in childhood and may not last into adulthood. In the U.S., it appears to be more common among African Americans, Asian Americans, and Pacific Islanders than other groups.

There is no cure for atopic dermatitis, but there are ways of alleviating and preventing the rash from forming.

This typically involves using a non-irritating moisturizer regularly, after bathing or showering. It is also important to avoid fragranced products, food allergens, and irritating fabrics, such as wool. In addition, a person may need a topical corticosteroid, which a doctor can recommend or prescribe.

Learn more about eczema on black skin and its treatments.

Psoriasis is a long-term inflammatory condition that causes thickened patches of skin. On skin of color, these patches may be red or violet and have a top layer of silver or gray scales.

In the U.S., psoriasis is more common in white people than Black people. However, in Black people, it may be more likely to cover larger areas of the body.

Psoriasis can affect the nails as well as the skin, and a significant portion of people with psoriasis also have arthritis.

There is no cure, but it is possible to manage the symptoms. Among the range of options are:

Learn more about psoriasis on black skin and its treatments.

Lichen planus causes a series of bumps to form on the skin. Each bump is shiny, raised, and has a flat top. On skin of color, these bumps may be gray-brown or purple.

The most commonly affected areas are the back, neck, lower legs, ankles, and the insides of the wrists. In 20% of cases, lichen planus causes no symptoms beyond the bumps, but in others, it causes intense itching.

Lichen planus can last for months or years, and there is no known cure. Treatments that can relieve the symptoms include:

Learn more about the causes and treatments of lichen planus.

Vitiligo is a condition that causes patches of skin to lose its color, or become depigmented. If the condition affects areas with hair, the hair may turn white, too.

The condition occurs when the immune system attacks melanocytes, the cells that produce melanin. Scientists are not sure why this happens, but they believe that it could stem from an autoimmune response.

Areas commonly affected by vitiligo include:

Vitiligo can affect anyone, but it is more noticeable in people with darker skin. People with vitiligo are more likely to have a family history of autoimmune disorders.

The depigmentation often stops or slows over time. Treatments focus on reducing the spread of depigmentation and restoring color to the skin. This may include the use of medicated creams or light therapy.

Shingles is caused by the same virus as chickenpox. Anyone who has had chickenpox can develop shingles later on. One symptom that most people with shingles develop is a rash of small blisters.

The symptoms of shingles are:

Some people also experience a fever, headaches, muscle aches, stomach pain, or nausea and vomiting.

On highly pigmented skin, a shingles rash may be red, the same color as the skin, or slightly darker. The scabs may be grey.

While the rash often heals within 24 weeks, it is important for anyone with shingles symptoms to see a doctor for treatment within 23 days. This is because shingles can cause long-term complications.

The doctor can prescribe antiviral medication, which can reduce the risk of complications and shorten the healing time.

Ringworm is a fungal infection of the skin. It often causes a round or ring-shaped rash with a raised border, though the rash may be shaped differently on certain areas, such as the feet or hands.

On darker skin, the ringworm rash is often gray or brown.

Ringworm is contagious, so it is important to seek treatment right away and avoid touching the rash, even if it is itchy.

Other names for this infection include:

Treatment may involve antifungal cream or, if the rash covers a large area, oral medication.

The best approach to treatment at home depends on the cause of the rash. But there are some general strategies for preventing further irritation, such as:

It is also important to protect the skin from sun damage with a product that contains SPF 30 or higher. UV light can also worsen skin irritation for people with certain conditions.

In some cases, a rash signals a medical emergency. Seek urgent medical attention if a rash:

Anyone who may have shingles or ringworm should see a doctor promptly to prevent transmission. For shingles, a person should wait no more than 23 days.

Otherwise, it is generally a good idea to contact a doctor if any rash lasts longer than a week.

The Skin of Color Society provide a database of dermatologists in the U.S. who have experience treating conditions in people of color.

In skin of color, a rash may be red, brown, purple, or gray.

Some doctors may misdiagnose skin issues in people of color due to a lack of awareness. Skin of color is often underrepresented in medical texts.

A dermatologist who understands how rashes present in the full range of skin tones is best prepared to provide the right treatment.

Read more here:
Rash on black skin: Pictures, symptoms, and treatments - Medical News Today

Skin Stem Cells Comments Off on Rash on black skin: Pictures, symptoms, and treatments – Medical News Today | December 24th, 2020

As for your lips, we dont grow hair there because our lips are made up of a different type of cell, as theyre considered to be an extension of the gastrointestinal (GI) tract, says Mariwalla.

If having hair is so crucial to the function of our bodies, why have we been removing it for hundreds of years? Well, we have no one to blame but ourselves. We have, through communication with one another, established a globalized practice of removing hair to make women especially look very smooth and have baby-like skin; and for men to retain their body hair, says Jablonski. We tend to think, Oh, these signals are very ancient. These practices are very ancient. They're not. This is a pretty recent obsession. Jablonski estimates the practice of body hair removal started about only 500 years ago.

While modern societal standards of what femininity and masculinity are still very much linked to hairiness or lack of hairiness, weve begun to see a shift in the acceptance and normalization of body hair, thanks in part to social media, which has even helped us celebrate body hair for the first time. (Remember #freeyourpits?)

It's really wonderful when people examine those social norms and say, hold on, who started this? This is a bunch of nonsense, says Jablonski. And they realize, Hey, I can be a beautiful person inside and out without following these practices. It is tremendously liberating.

That sense of celebration seems to be more prevalent than ever before, as were living through a pandemic, which has put physical interactions between people on pause. Because of this, many of the performances we put on for others, like body hair removal, have become one-woman shows, with one-woman audiences.

So then you realize, in your heart of hearts, this is a waste of time, says Jablonski. Why should I take this time to do this thing that is socially acceptable and allows me to cleave towards a social norm? I'm doing just fine. People feel a lot of freedom now.

Of course, if you do choose to remove your body hair and thats fine too! depending on the location of the hair, there are a number of methods that will get the job done, says Mariwalla.

Shaving

For starters, theres shaving, the act of removing hair with a razor. When you shave the hair on your body (typically on the legs, underarms, and face), youre removing hair from above the top layer of skin, says Mariwalla. She recommends shaving with a cream or gel to keep the skin hydrated. The process of shaving is almost like exfoliating that top layer of skin, she says. So, it's like a two for one.

Tweezing

Tweezing, on the other hand, pulls the hair directly from the follicle. When you think about a hair follicle, it's like the little house that your hair lives in, explains Mariwalla. Any time you pull a hair from a follicle, it's always going to grow back. But its going to take longer than when you only remove it from above the skin.

Waxing and Sugaring

Waxing and sugaring use the same mechanism as tweezing but with warm substances (i.e. wax and sugar) that sit on top of the skin and around the hair to coax it out of the follicle. Its a process that is trying to warm the skin, so that the hair follicle opens up a little bit and the wax solidifies around the hair, says Mariwalla. When you remove the wax you basically rip the hair out of the follicle as you're doing it.

Depilatory Cream

There are also depilatory creams. Instead of grabbing onto the hair and pulling it, you're putting on a chemical that's dissolving the hair at the root, explains Mariwalla. So then you basically then just wipe it away.

More here:
Everything You've Ever Wanted to Know About Body Hair - Allure

Skin Stem Cells Comments Off on Everything You’ve Ever Wanted to Know About Body Hair – Allure | December 24th, 2020

VANCOUVER, British Columbia, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Lui Franciosi is proud to announce the launch of his new YouTube channel. As a pharmacologist and former executive in the pharmaceutical industry, Dr. Franciosi’s videos will focus on topics related to health and pharma care, as well as topics related to entrepreneurship, seniors care and COVID-19.

See the original post:
Lui Franciosi of Franciosi Consulting Launches YouTube Channel

Global News Feed Comments Off on Lui Franciosi of Franciosi Consulting Launches YouTube Channel | December 24th, 2020

Annual Meeting to be adjourned solely with respect to Item 2, and Item 2 to be modified to decrease the proposed aggregate number of shares of common stock that the Company would be authorized to issue from 500,000,000 shares to 400,000,000 shares Annual Meeting to be adjourned solely with respect to Item 2, and Item 2 to be modified to decrease the proposed aggregate number of shares of common stock that the Company would be authorized to issue from 500,000,000 shares to 400,000,000 shares

Read more here:
Ocugen Inc. Announces Plan to Adjourn Annual Meeting of Stockholders, Modify Proposal Regarding Increase in Number of Authorized Shares

Global News Feed Comments Off on Ocugen Inc. Announces Plan to Adjourn Annual Meeting of Stockholders, Modify Proposal Regarding Increase in Number of Authorized Shares | December 24th, 2020

Will Trade on the Nasdaq Global Market Under Ticker “GBS” Will Trade on the Nasdaq Global Market Under Ticker “GBS”

Read more:
GBS Inc. Announces Pricing of Initial Public Offering

Global News Feed Comments Off on GBS Inc. Announces Pricing of Initial Public Offering | December 24th, 2020

Basel, 23 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer. “This approval represents a significant step forward in the treatment of HER2-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The innovation of Phesgo significantly reduces the time people spend receiving standard of care therapy with Perjeta and Herceptin, helping to minimise the impact of treatment on their everyday lives. It also addresses the increasing demand across healthcare systems for faster and more flexible treatment solutions.” Phesgo is available as a single-dose vial for SC injection and enables over 90% faster treatment than IV administration of standard of care therapy with Perjeta and Herceptin. SC administration of Phesgo takes approximately eight minutes for the initial loading dose and approximately five minutes for each subsequent maintenance dose. This is compared to approximately 150 minutes for infusion of a loading dose of Perjeta and Herceptin using the standard IV formulations, and between 60-150 minutes for subsequent maintenance infusions of the two medicines.4,5,6 The approval of Phesgo in Europe is based on results from the pivotal phase III FeDeriCa study, which showed that treatment with Phesgo produced non-inferior levels of Perjeta and Herceptin in the blood and demonstrated comparable efficacy versus IV administration of the two medicines. The safety profile of Phesgo with chemotherapy was comparable to IV administration of Perjeta plus Herceptin and chemotherapy. No new safety signals were identified, including no meaningful difference in cardiac toxicity.7 The development of Phesgo highlights Roche's commitment to improving patients’ experience of cancer treatment, looking beyond efficacy outcomes and focusing on more flexible treatment solutions. Phesgo has the potential to help minimise pressure on healthcare systems by reducing administration time, as well as other costs associated with treatment, such as time spent in the infusion chair and drug preparation.8,9 The COVID-19 pandemic has further highlighted the need to utilise novel approaches that help to manage healthcare capacity to free-up time and resources. About the FeDeriCa study7,10 FeDeriCa is an international, multi-centre, two-arm, randomised, open-label, pivotal phase III study evaluating the pharmacokinetics, efficacy and safety of subcutaneous injection of Phesgo in combination with chemotherapy, compared with standard intravenous (IV) infusions of Perjeta and Herceptin in combination with chemotherapy, in 500 people with HER2-positive early breast cancer treated in the neoadjuvant (before surgery) and adjuvant (after surgery) settings. The primary endpoint of the study is minimum levels of Perjeta in the blood during a given dosing interval (Ctrough), when compared to IV administration of Perjeta. Secondary endpoints include safety; minimum levels of Herceptin in the blood during a given dosing interval (Ctrough); and total pathological complete response, meaning there is no tumour tissue detectable in the tissue removed at the time of surgery. Data from the FeDeriCa study were presented at the San Antonio Breast Cancer Symposium in December 2019. The FeDeriCa study met its primary endpoint of non-inferior levels of Perjeta in the blood. The geometric mean ratio (GMR; a type of average used when assessing pharmacokinetics) for the primary endpoint was 1.22 (90% CI: 1.14 to 1.31), with the lower limit of the 90% CI of the GMR=1.14?0.80 (the pre-specified non-inferiority margin). A secondary endpoint of non-inferior levels of Herceptin was also met, with blood concentrations for people receiving Phesgo non-inferior to those receiving IV Herceptin (GMR=1.33 [90% CI: 1.24 to 1.43]; lower limit of 90% CI of GMR=1.24?0.80). A non-inferiority endpoint was chosen for the study to ensure that people were receiving sufficient dosing with Perjeta and Herceptin as compared to the established IV doses at the same treatment intervals. About Phesgo Phesgo combines the same monoclonal antibodies as Perjeta and Herceptin with Halozyme Therapeutics’ Enhanze® drug delivery technology in a novel formulation for subcutaneous (SC) use.4,11  This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC injection. Halozyme’s Enhanze drug delivery technology may enable and optimise SC drug delivery for appropriate co-administered therapeutics. The technology is based on a proprietary recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that temporarily degrades hyaluronan – a glycosaminoglycan or chain of natural sugars in the body – to aid in the dispersion and absorption of other injected therapeutic drugs.11 Pertuzumab in Phesgo is the same monoclonal antibody as in intravenous (IV) Perjeta, and trastuzumab in Phesgo is the same monoclonal antibody as in IV Herceptin. The mechanisms of action of Perjeta and Herceptin are believed to complement each other as both bind to the HER2 receptor, but in different locations. The combination of Perjeta and Herceptin is thought to provide a more comprehensive, dual blockade of the HER signalling pathways.12,13 Phesgo is approved in the US for the treatment of early and metastatic HER2-positive breast cancer. The approved indications for Phesgo mirror those of Perjeta. The standard IV formulation of Perjeta in combination with IV Herceptin and chemotherapy (the Perjeta-based regimen) is approved in more than 100 countries for the treatment of both early and metastatic HER2-positive breast cancer. In the neoadjuvant (before surgery) early breast cancer (eBC) setting, the Perjeta-based regimen has been shown to almost double the rate of pathological complete response compared to Herceptin and chemotherapy.14 Additionally, the combination has been shown to significantly reduce the risk of recurrence of invasive disease or death in the adjuvant (after surgery) eBC setting.15 In the metastatic setting, the combination has shown an unprecedented survival benefit in previously untreated (first-line) patients with HER2-positive metastatic breast cancer.16 About Roche’s medicines for HER2-positive breast cancer Roche has been leading research into the HER2 pathway for more than 30 years and is committed to improving the health, quality of life and survival of people with both early and metastatic HER2-positive disease. HER2-positive breast cancer is a particularly aggressive form of the disease that affects approximately 25-30% of patients.17 Roche has developed three innovative medicines that have helped transform the treatment of HER2-positive breast cancer: Herceptin, Perjeta and Kadcyla® (trastuzumab emtansine). Eligibility for treatment with Roche’s HER2-targeted medicines is determined via a diagnostic test which identifies people who will likely benefit from these medicines at the onset of their disease. About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] O’Shaugnessy J, et al. Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study. Presented at ESMO, 2020 Sept 19-21. Abstract #165MO.[2]  Xavier P, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14(10):962-70. [3] Tjalma, et al. Trastuzumab IV versus SC: A time, motion and cost assessment in a lean operating day care oncology unit. Presented at: SABCS; 2016 Dec 6-10; San Antonio, TX, USA. Abstract #P4-21-15. [4] US Food and Drug Administration. Prescribing information for Phesgo. [Internet; cited December 2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. [5] US Food and Drug Administration. Prescribing Information for Herceptin. [Internet; cited December 2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/. [6] US Food and Drug Administration. Prescribing information for Perjeta. [Internet; cited December 2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125409lbl.pdf. [7] Tan A. et al. Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study. Presented at SABCS; 2019 Dec 10-14; San Antonio, Texas. Abstract #PD4-07. [8] Sripada et al. Subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of metastatic breast cancer in Canada - a budget impact analysis. Presented at SABCS; 2020 Dec 08-11; San Antonio Texas: PS9-55. [9] Roche data on file. [10] Clinical trials.gov. A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer (FeDeriCa). [Internet: December 2020]. Available from: https://clinicaltrials.gov/ct2/show/NCT03493854. [11] Halozyme. Enhanze® Drug Delivery Technology. [Internet; cited December 2020]. Available from: https://www.halozyme.com/enhanze/overview/default.aspx. [12] Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014;2014:852748. [13] Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-75. [14] Gianni L, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32. [15] Minckwitz G, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;13;377(2):122-31. [16] Swain SM, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;19;372(8):724-34. [17] Jarrett A, et al. Experimentally-driven mathematical modelling to improve combination targeted and cytotoxic therapy for HER2+ breast cancer. Sci Rep. 2019;9:12830. Roche Group Media Relations Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Excerpt from:
European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with...

Global News Feed Comments Off on European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with… | December 24th, 2020

COPENHAGEN, Denmark, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Evaxion Biotech, a clinical-stage biotechnology company developing AI-driven immunotherapies, announces today the dosing of the first patient in a Phase I/IIa clinical trial of its adjuvant immunotherapy EVX-02, in combination with checkpoint inhibitors in patients with advanced melanoma.

See the rest here:
Evaxion Biotech Doses First Patient in Phase I/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors

Global News Feed Comments Off on Evaxion Biotech Doses First Patient in Phase I/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors | December 24th, 2020

VANCOUVER, Dec. 22, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) CSE: BETR / OTCQB: BETRF / FRA: NPAU) an emerging biotech company, is pleased to announce that Patrick Kroupa and Justin Kirkland, two industry leaders in psychedelic therapeutics, have joined the Company. Mr. Kroupa and Mr. Kirkland will join the senior management team of BetterLife as Chief Psychedelics Officer and Chief Psychedelics Scientist, respectively.

Go here to read the rest:
BetterLife Welcomes Psychedelic Industry Leaders to the Senior Management Team

Global News Feed Comments Off on BetterLife Welcomes Psychedelic Industry Leaders to the Senior Management Team | December 24th, 2020

Novadip Biosciences Receives Rare Paediatric Disease Priority Review and Orphan Disease Designation

Visit link:
Novadip Biosciences Receives Rare Paediatric Disease Priority Review and Orphan Disease Designation

Global News Feed Comments Off on Novadip Biosciences Receives Rare Paediatric Disease Priority Review and Orphan Disease Designation | December 24th, 2020

The Company began enrolling patients in Saturn-1 in September 2020 and expects to initiate its second pivotal registration trial, Saturn-2, in 2021 The Company began enrolling patients in Saturn-1 in September 2020 and expects to initiate its second pivotal registration trial, Saturn-2, in 2021

Read the rest here:
Tarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candidate TP-03

Global News Feed Comments Off on Tarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candidate TP-03 | December 24th, 2020

NEW YORK, NY, REHOVAT, ISRAEL, SINGAPORE, Dec. 23, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced that it has entered into a preferred vendor agreement to supply COVID-19 related testing products and services to Natural Wellness Clinics (“NWC”) for use in its efforts in testing the uninsured population in the Commonwealth of Kentucky. NWC is a US military veteran owned health care provider that offers communities a holistic and integrative approach and is establishing a niche in implementing large-scale testing programs and logistics for state governments that it hopes may dovetail into vaccine distribution logistics.

Continued here:
Todos Medical Announces Agreement to Supply Natural Wellness Clinics with COVID-19 Testing Products to Support Initiatives in the Commonwealth of...

Global News Feed Comments Off on Todos Medical Announces Agreement to Supply Natural Wellness Clinics with COVID-19 Testing Products to Support Initiatives in the Commonwealth of… | December 24th, 2020

--Dr. Dunne resigns as Chief Scientific Officer---- Steven Aronin, M.D., Senior Vice President and Head of Clinical Development, to lead Development and Regulatory Activities--

Go here to read the rest:
Iterum Therapeutics Announces Transition of Michael Dunne, M.D. to Strategic Advisor and Member of the Board of Directors

Global News Feed Comments Off on Iterum Therapeutics Announces Transition of Michael Dunne, M.D. to Strategic Advisor and Member of the Board of Directors | December 24th, 2020

NEW YORK and MAINZ, GERMANY, December 23, 2020 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the companies’ COVID-19 vaccine from production facilities in the U.S. This agreement brings the total number of doses to be delivered to the U.S. to 200 million. The companies expect to deliver the full 200 million doses to Operation Warp Speed (OWS) by July 31, 2021. Consistent with the original agreement announced in July 2020, the U.S. government will pay $1.95 billion for the additional 100 million doses.

Read the original post:
Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine

Global News Feed Comments Off on Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine | December 24th, 2020

Read the original:
Avicanna to Expand Access to Its Advanced and Evidence-Based RHO Phyto Medical Products Through Provincial Retailers Across Canada

Global News Feed Comments Off on Avicanna to Expand Access to Its Advanced and Evidence-Based RHO Phyto Medical Products Through Provincial Retailers Across Canada | December 24th, 2020

SAN FRANCISCO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- UC San Francisco (UCSF) and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients.

See the original post here:
UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases

Global News Feed Comments Off on UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases | December 24th, 2020

TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the “Company”), a consumer packaged goods company in the cannabis products market, is thrilled to announce that its wholly owned subsidiary, KGK Science Inc. (“KGK”) has received its Institutional Cannabis Research Licence from Health Canada pursuant to the Cannabis Act. In addition to the two project-specific cannabis research licences, and the licence to conduct sensory trials currently held by KGK, this Institutional licence provides the contract research organization with approval to conduct multiple cannabis research projects, removing the need to obtain individual research licences for each project, thereby increasing its flexibility and expediting processes at its clinical research facility located in London, Ontario.

See original here:
Auxly’s Subsidiary KGK Science Receives Institutional Cannabis Research Licence from Health Canada

Global News Feed Comments Off on Auxly’s Subsidiary KGK Science Receives Institutional Cannabis Research Licence from Health Canada | December 24th, 2020

NEW YORK and MAINZ, GERMANY, December 23, 2020 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the companies’ COVID-19 vaccine from production facilities in the U.S. This agreement brings the total number of doses to be delivered to the U.S. to 200 million. The companies expect to deliver the full 200 million doses to Operation Warp Speed (OWS) by July 31, 2021. Consistent with the original agreement announced in July 2020, the U.S. government will pay $1.95 billion for the additional 100 million doses.

See the original post here:
Correction: Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine

Global News Feed Comments Off on Correction: Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine | December 24th, 2020

Read the original:
Recce Announces Positive Intranasal Animal Data against SARS-CoV-2 in International Study

Global News Feed Comments Off on Recce Announces Positive Intranasal Animal Data against SARS-CoV-2 in International Study | December 24th, 2020

Continued here:
AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers’

Global News Feed Comments Off on AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers’ | December 24th, 2020